The immune system holds the key to lasting protection
Today's leading immunotherapies are monoclonal antibodies, which are very costly and involve long infusions.
OUR SOLUTION
Our platform trains the immune system to fight pathological proteins that cause chronic conditions
But today’s leading immunotherapies rely on infusions, cost six figures, and target too little of the disease. That’s not sustainable for the millions living with complex, lifelong conditions.
Founded by experts in neurology, immunology, and biotech
Our team includes former Biogen and Merck leadership, neurovirologists, and the researchers who first linked HERV-K to ALS. Backed by institutional grants and $60M in platform R&D.
